Anika Therapeutics Inc (NAS:ANIK)
$ 17.35 -0.2 (-1.14%) Market Cap: 254.10 Mil Enterprise Value: 219.27 Mil PE Ratio: 0 PB Ratio: 1.42 GF Score: 70/100

Q2 2021 Anika Therapeutics Inc Earnings Call Transcript

Aug 05, 2021 / 09:00PM GMT
Release Date Price: $41.09 (+2.60%)
Operator

Good day, everyone, and welcome to Anika's Second Quarter 2021 Earnings Conference Call. As a reminder, this call is being recorded.

I would now like to turn the call over to Mr. Mark Namaroff, Executive Director of Investor Relations and Corporate Communications. Please go ahead, sir.

Mark Namaroff
Anika Therapeutics, Inc. - Executive Director of IR & Corporate Communications

Thank you. Good evening, everyone, and welcome to Anika's Second Quarter Conference Call and webcast. Our Q2 earnings press release was issued after the close of the market today and is available on our Investor Relations website located at www.anika.com, as are our supplementary PowerPoint slides that will be used for the discussion today.

With me on the call today are Dr. Cheryl Blanchard, President and Chief Executive Officer; and Mike Levitz, Executive Vice President, Chief Financial Officer and Treasurer. During today's call, Cheryl and Mike will review Anika's second quarter 2021 financial results

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot